Intra-Cellular Therapies
Stock Forecast, Prediction & Price Target
Intra-Cellular Therapies (ITCI) stock Price Target by analysts
$85.5
Potential downside: -35.16%
Intra-Cellular Therapies price prediction
What is Intra-Cellular Therapies stock analysts` prediction?
Intra-Cellular Therapies stock forecast: Based on 2 Wall Street analysts` predicted price targets for Intra-Cellular Therapies in the last 3 months, the avarage price target is $85.5, with a high forecast of $NaN. The average price target represents a -35.16% change from the last price of $131.87.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Intra-Cellular Therapies stock Price Target by analysts
Full breakdown of analysts given Intra-Cellular Therapies price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Corinne Jenkins Goldman Sachs | 33.33% 1/3 | 10 months ago | $79 -40.09% downside | $85.47 | StreetInsider | Previous targets (2) |
David Amsellem Piper Sandler | 0% 0/1 | about 1 year ago | $92 -30.23% downside | $72.42 | TheFly | Previous targets (0) |
Brian Abrahams RBC Capital | 0% 0/3 | about 1 year ago | $106 -19.61% downside | $73.63 | StreetInsider | Previous targets (2) |
Corinne Jenkins Goldman Sachs | 33.33% 1/3 | about 1 year ago | $74 -43.88% downside | $73.63 | TheFly | Previous targets (2) |
Ami Fadia Needham | 0% 0/2 | about 1 year ago | $100 -24.16% downside | $74.86 | StreetInsider | Previous targets (1) |
Ashwani Verma UBS | 0% 0/2 | about 1 year ago | $83 -37.05% downside | $72.42 | StreetInsider | Previous targets (1) |
Graig Suvannavejh Mizuho Securities | 0% 0/1 | about 1 year ago | $100 -24.16% downside | $76.06 | StreetInsider | Previous targets (0) |
Brian Abrahams RBC Capital | 0% 0/3 | about 1 year ago | $103 -21.89% downside | $75.48 | StreetInsider | Previous targets (2) |
Andrew Tsai Jefferies | 0% 0/1 | over 1 year ago | $105 -20.37% downside | $70.08 | StreetInsider | Previous targets (0) |
Brian Abrahams RBC Capital | 0% 0/3 | over 1 year ago | $96 -27.20% downside | $71.21 | StreetInsider | Previous targets (2) |
Sumant Kulkarni Canaccord Genuity | 0% 0/1 | over 1 year ago | $107 -18.85% downside | $74.54 | StreetInsider | Previous targets (0) |
Joel Beatty Robert W. Baird | 0% 0/1 | over 1 year ago | $103 -21.89% downside | $79.84 | StreetInsider | Previous targets (0) |
Ami Fadia Needham | 0% 0/2 | over 1 year ago | $82 -37.81% downside | $67.21 | TheFly | Previous targets (1) |
Ashwani Verma UBS | 0% 0/2 | about 3 years ago | $75 -43.12% downside | $53.07 | TheFly | Previous targets (1) |
Corinne Jenkins Goldman Sachs | 33.33% 1/3 | over 3 years ago | $64 -51.46% downside | $57.49 | Pulse 2.0 | Previous targets (2) |
Intra-Cellular Therapies Financial Estimates
Intra-Cellular Therapies Revenue Estimates
Intra-Cellular Therapies EBITDA Estimates
Intra-Cellular Therapies Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $81.70M N/A | $249.13M 204.90% | $464.37M 86.39% | Avg: $925.70M Low: $817.49M High: $1.00B avg. 99.34% | Avg: $1.33B Low: $1.22B High: $1.43B avg. 44.24% | Avg: $1.83B Low: $1.68B High: $1.96B avg. 37.44% | Avg: $2.47B Low: $2.27B High: $2.65B avg. 35.06% |
Net Income
% change YoY
| $-284.12M N/A | $-256.25M 9.80% | $-139.67M 45.49% | Avg: $119.31M Low: $-39.89M High: $312.57M avg. 185.42% | Avg: $387.64M Low: $65.94M High: $724.86M avg. 224.88% | Avg: $670.35M Low: $597.49M High: $733.10M avg. 72.92% | Avg: $1.08B Low: $963.00M High: $1.18B avg. 61.17% |
EBITDA
% change YoY
| $-285.68M N/A | $-263.62M 7.72% | $-158.85M 39.74% | Avg: $-804.20M Low: $-869.20M High: $-710.19M avg. -406.25% | Avg: $-1.16B Low: $-1.24B High: $-1.06B avg. -44.24% | Avg: $-1.59B Low: $-1.70B High: $-1.46B avg. -37.44% | Avg: $-2.15B Low: $-2.30B High: $-1.97B avg. -35.06% |
EPS
% change YoY
| -$3.5 N/A | -$2.72 22.28% | -$1.46 46.32% | Avg: $1.14 Low: -$0.42 High: $3.26 avg. 178.4% | Avg: $3.58 Low: $0.69 High: $7.56 avg. 212.88% | Avg: $6.99 Low: $6.23 High: $7.65 avg. 95.21% | Avg: $11.27 Low: $10.04 High: $12.32 avg. 61.17% |
Operating Expenses
% change YoY
| $359.36M N/A | $492.31M 36.99% | $590.00M 19.84% | Avg: $200.96B Low: $177.46B High: $217.20B avg. 33960.94% | Avg: $289.88B Low: $265.64B High: $310.75B avg. 44.24% | Avg: $398.41B Low: $365.10B High: $427.10B avg. 37.44% | Avg: $538.12B Low: $493.13B High: $576.87B avg. 35.06% |
FAQ
What is Intra-Cellular Therapies stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 136.10% in 2025-2028.
We have gathered data from 11 analysts. Their low estimate is -39.89M, average is 119.31M and high is 312.57M.
What is Intra-Cellular Therapies stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 54.02% in 2025-2028.
We have gathered data from 12 analysts. Their low revenue estimate is $817.49M, average is $925.70M and high is $1.00B.
What is Intra-Cellular Therapies stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 136.91% in 2025-2028.
We have gathered data from 11 analysts. Their low earnings per share estimate is -$0.42, average is $1.14 and high is $3.26.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Intra-Cellular Therapies stock. The most successful analyst is Corinne Jenkins whose win rate is 33.33%. He has correctly predicted 1/3 price targets.